Arrowhead Pharmaceuticals Inc ARWR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Trading Information
- Previous Close Price
- $47.15
- Day Range
- $44.55–47.79
- 52-Week Range
- $37.15–95.39
- Bid/Ask
- $44.33 / $50.96
- Shares Outstanding
- 141.37M
- Market Cap
- $6.68B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 29.47
- Price/Sales
- 14.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 711
Valuation
Metric | ARWR |
|---|---|
Price/Earnings (Normalized) | 29.47 |
Price/Book Value | 132.41 |
Price/Sales | 14.81 |
Price/Cash Flow | — |
Price/Earnings
ARWR
Financial Strength
Metric | ARWR |
|---|---|
Quick Ratio | 3.86 |
Current Ratio | 4.14 |
Interest Coverage | −7.34 |
Quick Ratio
ARWR
Profitability
Metric | ARWR |
|---|---|
Return on Assets (Normalized) | −38.00% |
Return on Equity (Normalized) | −159.92% |
Return on Invested Capital (Normalized) | −56.28% |
Return on Assets
ARWR
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Yp&RLg | LOCK|NM&M# | $138B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%T%$^j | LOCK|H?^X | $98B | |||
| Moderna Inc MRNA | LOCK|C%RM&R% | LOCK|s<N | $94B | |||
| argenx SE ADR ARGX | LOCK|<hDdS>t | LOCK|Lm% | $62B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|&<##>!c | LOCK|#r | $50B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|S#Y?#Zr | LOCK|$%K!> | $31B | |||
| Incyte Corp INCY | LOCK|Cs!z#T> | LOCK|q^K | $25B | |||
| BioNTech SE ADR BNTX | LOCK|%bTJ<# | LOCK|!Zk | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|bCX>!^ | LOCK|!x>> | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|<>!&cqZ | LOCK|<h | $15B |
United States